Literature DB >> 23736520

Interventional cardiology: Indications for renal denervation: a balanced approach?

George L Bakris.   

Abstract

Renal denervation for the treatment of resistant hypertension is approved in Europe and is being studied in the USA. A newly published ESC consensus document integrates all the published data on this procedure, and summarizes how best to define, evaluate, and follow up patients who are candidates for the procedure.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23736520     DOI： 10.1038/nrcardio.2013.85

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


  10 in total

1.  Incidence and prognosis of resistant hypertension in hypertensive patients.

Authors:  Stacie L Daugherty; J David Powers; David J Magid; Heather M Tavel; Frederick A Masoudi; Karen L Margolis; Patrick J O'Connor; Joe V Selby; P Michael Ho
Journal:  Circulation       Date:  2012-02-29       Impact factor: 29.690

2.  Expert consensus document from the European Society of Cardiology on catheter-based renal denervation.

Authors:  Felix Mahfoud; Thomas Felix Lüscher; Bert Andersson; Iris Baumgartner; Renata Cifkova; Carlo Dimario; Pieter Doevendans; Robert Fagard; Jean Fajadet; Michel Komajda; Thierry Lefèvre; Chaim Lotan; Horst Sievert; Massimo Volpe; Petr Widimsky; William Wijns; Bryan Williams; Stephan Windecker; Adam Witkowski; Thomas Zeller; Michael Böhm
Journal:  Eur Heart J       Date:  2013-04-25       Impact factor: 29.983

Review 3.  Resistant hypertension--its identification and epidemiology.

Authors:  Pantelis A Sarafidis; Panagiotis Georgianos; George L Bakris
Journal:  Nat Rev Nephrol       Date:  2012-11-20       Impact factor: 28.314

4.  Effect of spironolactone on blood pressure in subjects with resistant hypertension.

Authors:  Neil Chapman; Joanna Dobson; Sarah Wilson; Björn Dahlöf; Peter S Sever; Hans Wedel; Neil R Poulter
Journal:  Hypertension       Date:  2007-02-19       Impact factor: 10.190

5.  Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction.

Authors:  Ana M Briones; Aurelie Nguyen Dinh Cat; Glaucia E Callera; Alvaro Yogi; Dylan Burger; Ying He; Jose W Corrêa; Anne Marie Gagnon; Celso E Gomez-Sanchez; Elise P Gomez-Sanchez; Alexander Sorisky; Teik Chye Ooi; Marcel Ruzicka; Kevin D Burns; Rhian M Touyz
Journal:  Hypertension       Date:  2012-04-09       Impact factor: 10.190

6.  Interaction between Adiponectin and Aldosterone.

Authors:  Colleen Flynn; George L Bakris
Journal:  Cardiorenal Med       Date:  2011-04-15       Impact factor: 2.041

7.  Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

Authors:  David A Calhoun; Daniel Jones; Stephen Textor; David C Goff; Timothy P Murphy; Robert D Toto; Anthony White; William C Cushman; William White; Domenic Sica; Keith Ferdinand; Thomas D Giles; Bonita Falkner; Robert M Carey
Journal:  Hypertension       Date:  2008-04-07       Impact factor: 10.190

8.  Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial.

Authors:  David E Kandzari; Deepak L Bhatt; Paul A Sobotka; William W O'Neill; Murray Esler; John M Flack; Barry T Katzen; Martin B Leon; Joseph M Massaro; Manuela Negoita; Suzanne Oparil; Krishna Rocha-Singh; Craig Straley; Raymond R Townsend; George Bakris
Journal:  Clin Cardiol       Date:  2012-05-09       Impact factor: 2.882

9.  Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension.

Authors:  Jens Jordan; Volkan Yumuk; Markus Schlaich; Peter M Nilsson; Barbara Zahorska-Markiewicz; Guido Grassi; Roland E Schmieder; Stefan Engeli; Nick Finer
Journal:  J Hypertens       Date:  2012-06       Impact factor: 4.844

Review 10.  State of hypertension management in the United States: confluence of risk factors and the prevalence of resistant hypertension.

Authors:  Pantelis A Sarafidis; George L Bakris
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-02       Impact factor: 3.738
  10 in total
  2 in total

Review 1.  Carotid baroreflex activation therapy for resistant hypertension.

Authors:  Ronald G Victor
Journal:  Nat Rev Cardiol       Date:  2015-07-07       Impact factor: 32.419

Review 2.  Renal denervation--implications for chronic kidney disease.

Authors:  Roland Veelken; Roland E Schmieder
Journal:  Nat Rev Nephrol       Date:  2014-04-15       Impact factor: 28.314
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.